CN112535217A - 母乳化的低致敏型鲜活婴幼儿配方奶及其制备方法 - Google Patents
母乳化的低致敏型鲜活婴幼儿配方奶及其制备方法 Download PDFInfo
- Publication number
- CN112535217A CN112535217A CN202011441206.XA CN202011441206A CN112535217A CN 112535217 A CN112535217 A CN 112535217A CN 202011441206 A CN202011441206 A CN 202011441206A CN 112535217 A CN112535217 A CN 112535217A
- Authority
- CN
- China
- Prior art keywords
- milk
- fresh
- hypoallergenic
- infant formula
- emulsified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 63
- 230000000774 hypoallergenic effect Effects 0.000 title claims abstract description 41
- 235000013336 milk Nutrition 0.000 title claims abstract description 40
- 239000008267 milk Substances 0.000 title claims abstract description 40
- 210000004080 milk Anatomy 0.000 title claims abstract description 40
- 230000008774 maternal effect Effects 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 235000020256 human milk Nutrition 0.000 claims abstract description 26
- 210000004251 human milk Anatomy 0.000 claims abstract description 24
- 235000020251 goat milk Nutrition 0.000 claims abstract description 14
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 235000016709 nutrition Nutrition 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 50
- 239000002131 composite material Substances 0.000 claims description 20
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 13
- 229920001542 oligosaccharide Polymers 0.000 claims description 13
- 150000002482 oligosaccharides Chemical class 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 235000020247 cow milk Nutrition 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 235000021388 linseed oil Nutrition 0.000 claims description 8
- 239000000944 linseed oil Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000008169 grapeseed oil Substances 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 6
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 6
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 6
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 6
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 6
- 102000007544 Whey Proteins Human genes 0.000 claims description 6
- 108010046377 Whey Proteins Proteins 0.000 claims description 6
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 6
- 229940114079 arachidonic acid Drugs 0.000 claims description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims description 6
- 235000019864 coconut oil Nutrition 0.000 claims description 6
- 239000003240 coconut oil Substances 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 5
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 5
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims description 5
- 244000298697 Actinidia deliciosa Species 0.000 claims description 5
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims description 5
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 5
- 241000167854 Bourreria succulenta Species 0.000 claims description 5
- 240000007651 Rubus glaucus Species 0.000 claims description 5
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 5
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 5
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 5
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 5
- 235000019693 cherries Nutrition 0.000 claims description 5
- 239000002285 corn oil Substances 0.000 claims description 5
- 235000005687 corn oil Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005862 Whey Substances 0.000 claims description 3
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 3
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims description 3
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 235000021119 whey protein Nutrition 0.000 claims description 3
- 235000009434 Actinidia chinensis Nutrition 0.000 claims description 2
- 238000009928 pasteurization Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 7
- 208000026935 allergic disease Diseases 0.000 abstract description 6
- 230000007815 allergy Effects 0.000 abstract description 6
- 230000000975 bioactive effect Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 235000020185 raw untreated milk Nutrition 0.000 abstract description 3
- 239000004519 grease Substances 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000000717 retained effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 27
- 239000012228 culture supernatant Substances 0.000 description 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 240000006024 Lactobacillus plantarum Species 0.000 description 8
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 8
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 description 8
- 241000186315 Lactobacillus paracasei N1115 Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 241001052560 Thallis Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 5
- 238000009629 microbiological culture Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000007413 intestinal health Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- -1 2' -fucosyllactose Chemical class 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000008944 intestinal immunity Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 235000020200 pasteurised milk Nutrition 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000011506 response to oxidative stress Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004392 development of vision Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000020215 hypoallergenic milk formula Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/10—Whey; Whey preparations containing inorganic additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Dairy Products (AREA)
Abstract
本发明属于食品技术领域,公开了一种母乳化的低致敏型鲜活婴幼儿配方奶及其制备方法,是取牛乳/羊乳经巴氏杀菌后,加入营养剂混匀,再经均质、杀菌、冷却,然后加入辅料混匀,制得适于婴幼儿食用的母乳化的低致敏型鲜活婴幼儿配方奶。本发明通过模拟母乳(中国)的营养成分,合理配比蛋白质,调整油脂比例,优化原料配比和加工工艺,在降低因动物源乳成分差异引起的婴幼儿食源性过敏风险的同时,最大程度的保留生牛乳/生羊乳中的生物活性成分,解决了因动物源乳成分差异引起的婴幼儿食源性过敏风险。
Description
技术领域
本发明属于食品技术领域,涉及一种婴幼儿液态奶,具体地说是一种母乳化的低致敏型鲜活婴幼儿配方奶及其制备方法。
背景技术
研究表明,在婴儿能够自己摄入和消化其他外源食品之前,母乳是婴儿生长发育、抵御外界细菌和病毒入侵的最重要的营养成分来源,能够为其提供免疫球蛋白、乳铁蛋白、骨桥蛋白等多种能够增强婴幼儿免疫力的活性蛋白质,以及低聚糖、核苷酸、神经节苷脂等生物活性成分。母乳喂养受到极大的重视,婴幼儿配方奶粉及液态奶的研发也越来越趋向于母乳组成。婴幼儿配方液态奶与奶粉的功能相同,是一种可直接喂食婴幼儿的液态乳制品,具有无需冲调、温热后即食的优点。配方奶依赖于牛乳、羊乳等,由于物种差异,动物源乳与母乳中的各种营养素存在着较大差异,同时也增加了婴幼儿发生食源性过敏的风险。而氨基酸、脂质结构及脂肪酸、其它生物活性成分的含量等影响着婴幼儿成长发育,因此,依据母乳营养组成以及婴幼儿的生长发育需求,研制更接近母乳、致敏风险小且食用简单方便的婴幼儿配方奶具有重要意义。
发明内容
本发明的目的,是要提供一种母乳化的低致敏型鲜活婴幼儿配方奶,以解决因动物源乳成分差异引起的婴幼儿食源性过敏风险的问题;
本发明的另一个目的,是要提供上述母乳化的低致敏型鲜活婴幼儿配方奶的一种制备方法。
为了实现上述目的,本发明采用的技术方案是:
一种母乳化的低致敏型鲜活婴幼儿配方奶,以重量份数计,制成它的有效成分的原料包括:
①牛乳/羊乳40~55份;
②营养剂:脱盐乳清粉20~35份、浓缩乳清蛋白粉0.5~10份、乳糖5~8份、无水奶油2~5份、复合植物油2~5份、1,3-二油酸-2-棕榈酸甘油三酯粉3~5份、复合母乳低聚糖0.5~3份、磷脂0.1~1份、DHA藻油粉0.1~0.5份、花生四烯酸粉剂0.1~0.3份、碳酸钙0.2~0.6份、核苷酸0.01~0.06份、复合维生素0.1~0.5份和复合矿物质0.1~0.3份;
③辅料:复合果粉0.1~1份和后生元0.1~2份。
作为一种限定,所述后生元是动物双歧杆菌乳亚种i797、鼠李糖乳杆菌x253、副干酪乳杆菌N1115及植物乳杆菌N3117的热灭活菌体和/或动物双歧杆菌乳亚种i797培养上清液浓缩物、鼠李糖乳杆菌x253培养上清液浓缩物、副干酪乳杆菌N1115培养上清液浓缩物及植物乳杆菌N3117培养上清液浓缩物的混合物。
作为另一种限定,以重量份数计,所述复合植物油是由玉米油3~5重量份、葡萄籽油1~3重量份、亚麻籽油1~3重量份和椰子油1~3重量份混合而成。
作为第三种限定,所述复合母乳低聚糖是由2'-岩藻糖基乳糖8~10重量份、乳糖-N-新四糖2~4重量份、乳糖-N-四糖2~4重量份、3'-唾液酸乳糖1~3重量份和6'-唾液酸乳糖1~3重量份混合而成。
作为第四种限定,以重量份数计,所述复合果粉是由樱桃粉1~3重量份、树莓粉0.5~1重量份和猕猴桃粉0.5~1重量份混合而成。
作为第五种限定,所述牛乳/羊乳是生牛乳/生羊乳经标准化、杂质分离制得。
本发明还提供了上述母乳化的低致敏型鲜活婴幼儿配方奶的一种制备方法,它是取牛乳/羊乳经巴氏杀菌后,加入营养剂混匀,再经均质、杀菌、冷却,然后加入辅料混匀,即得所述母乳化的低致敏型鲜活婴幼儿配方奶。
作为一种限定,所述加入营养剂混匀后且所述均质前,还需预热至60~65℃。
作为第二种限定,所述均质的压力为190~210bar。
作为第三种限定,所述巴氏杀菌的温度为52~58℃、时间为5~10s;
所述杀菌的温度为90~100℃、时间为5~10s。
由于采用了上述技术方案,本发明与现有技术相比,所取得的技术进步在于:
本发明通过模拟母乳(中国)的营养成分,合理配比蛋白质,调整油脂比例,优化原料配比和加工工艺,在降低因动物源乳成分差异引起的婴幼儿食源性过敏风险的同时,最大程度的保留生牛乳/生羊乳中的生物活性成分;
本发明中添加了后生元,为动物双歧杆菌乳亚种i797、鼠李糖乳杆菌x253、副干酪乳杆菌N1115和植物乳杆菌N3117的热灭活菌体及其培养上清浓缩物,具有促进肠道发育、调节婴幼儿胃肠道健康、抑制致病菌等健康功能,其还能够与复合母乳低聚糖、复合果粉协同增益,发挥提高免疫力、改善过敏反应和慢性炎症反应的功能;
本发明中添加了玉米油、葡萄籽油、亚麻籽油和椰子油。其中,葡萄籽油含有丰富的不饱和脂肪酸,以亚油酸和油酸为主要组成成分,亚油酸是人体必需脂肪酸,代谢后可产生花生四烯酸,花生四烯酸和DHA对视网膜和神经系统的发育有重要作用。葡萄籽油还含有植物甾醇和多酚类物质,具有良好的抗氧化活性,有助于预防婴幼儿成长后期的的肥胖发生;
亚麻籽油含有丰富的人体必需氨基酸,α-亚麻酸含量高达40%以上,能够直接成为细胞膜的组成物质,参与代谢形成EPA和DHA等重要的多不饱和脂肪酸促进大脑发育和保护视力。亚麻籽油还含有丰富的维生素E、甾醇、膳食纤维以及其特有的亚麻肽等,能够提高人体的免疫功能、预防过敏反应和慢性炎症反应;
椰子油具有椰香味,且富含中链脂肪酸,能不经酶解过程直接被小肠吸收,减少在体内的蓄积,迅速为婴幼儿提供能量;
本发明添加了2'-岩藻糖基乳糖、乳糖-N-新四糖、乳糖-N-四糖、3'-唾液酸乳糖和6'-唾液酸乳糖等多种母乳低聚糖,使配方奶更贴近母乳成分,同时能够促进婴幼儿肠道内双歧杆菌增殖,维护肠道微生态稳定。其中,3'-唾液酸乳糖和6'-唾液酸乳糖还能够提供唾液酸,促进婴幼儿大脑发育;
本发明中也添加了樱桃粉、树莓粉、猕猴桃粉,除了提供独特的果味外,还富含花青素、矿物质和维生素,能够增强婴幼儿体质、改善大脑功能、缓解慢性炎症和抗氧化等功能;
本发明的母乳化的低致敏型鲜活婴幼儿配方奶适用于婴幼儿食用。
附图说明
图1是本发明实施例8中测定的对照组与干预组GY11~GY13的小鼠粪便中双歧杆菌总数变化曲线;
图2是本发明实施例9中测定的对照组与干预组GY21~GY24的小鼠生长速率变化曲线;
图3是本发明实施例9中测定的对照组与干预组GY21~GY24的小鼠粪便中IgA含量对比图;
图4是本发明实施例9中测定的对照组与干预组GY21~GY24的小鼠血清中IgA含量对比图;
图5是本发明实施例9中测定的对照组与干预组GY21~GY24的小鼠血清中IgE含量对比图;
图6是本发明实施例9中测定的对照组与干预组GY21~GY24的小鼠血清中组胺含量对比图。
具体实施方式
下面通过具体实施例对本发明做进一步详细说明,应当理解所描述的实施例仅用于解释本发明,并不限定本发明。
实施例1一种母乳化的低致敏型鲜活婴幼儿配方奶的制备方法
一)后生元的制备
取动物双歧杆菌乳亚种i797、鼠李糖乳杆菌x253、副干酪乳杆菌N1115及植物乳杆菌N3117分别接种至MRS液体培养基37℃培养至菌数为1×1010CFU/mL时离心,分别收集相应的菌体和相应的培养上清液;
其中,动物双歧杆菌乳亚种i797菌体、鼠李糖乳杆菌x253菌体、副干酪乳杆菌N1115菌体及植物乳杆菌N3117菌体,按活菌数3:1:1:2:1的比例混合后,经110℃热灭活,得热灭活菌体;
分别取动物双歧杆菌乳亚种i797菌体培养上清液、鼠李糖乳杆菌x253菌体培养上清液、副干酪乳杆菌N1115菌体培养上清液及植物乳杆菌N3117培养上清液采用超滤技术进行浓缩,所得相应的培养上清液浓缩物按重量比3:1:1:2:1混合后,得培养上清液浓缩物的混合物;
热灭活菌体与培养上清液浓缩物的混合物混合,即为后生元。
需要注意,这里也可单独使用热灭活菌体或培养上清液浓缩物作为后生元使用。另,这里的相应的菌株培养条件仅为实际工业生产中的培养条件和处理条件,并不仅仅限于本实施例的范围,其中,处理方法按一般操作方法进行,培养条件的范围可参考相应菌株对应专利所保护的范围,具体参考如下。
其中,鼠李糖乳杆菌x253(Lactobacillus rhamnosus x253)已于2019年8月20日,在位于北京市朝阳区北辰西路1号院3号的中国微生物菌种保藏管理委员会普通微生物中心(国家专利局指定专利微生物保藏中心)进行保藏,保藏编号:CGMCC No.18404,其在专利申请号为202010258772.0的在先专利中首次公开;
动物双歧杆菌乳亚种i797(Bifidobacterium animalis subsp.lactis i797)已于2019年8月20日,在位于北京市朝阳区北辰西路1号院3号的中国微生物菌种保藏管理委员会普通微生物中心(国家专利局指定专利微生物保藏中心)进行保藏,保藏编号:CGMCCNo.18403,其在专利申请号为202010259210.8的在先专利中首次公开;
副干酪乳杆菌N1115(Lactobacillus paracasei N1115),已于2011年3月17日,在位于北京市朝阳区北辰西路1号院3号的中国微生物菌种保藏管理委员会普通微生物中心(国家专利局指定专利微生物保藏中心)进行保藏,保藏编号:CGMCC No.4691,其在专利号为201110357058.8的中国发明专利中首次公开;
植物乳杆菌N3117(Lactobacillus plantarum N3117),已于2014年12月5日,在位于北京市朝阳区北辰西路1号院3号的中国微生物菌种保藏管理委员会普通微生物中心(国家专利局指定专利微生物保藏中心)进行保藏,保藏编号:CGMCC No.10133,其在专利号为201510936243.0的中国发明专利中首次公开。
二)母乳化的低致敏型鲜活婴幼儿配方奶的制备
1)验收、净乳
取生牛乳进行标准化后,再经杂质分离,得牛乳。
2)预巴杀
取50kg牛乳经55℃巴氏杀菌8s后,降至室温,得巴氏奶。
3)混料
取2.22kg玉米油、0.56kg葡萄籽油、1.11kg亚麻籽油和1.11kg椰子油,作为复合植物油。其中,玉米油、葡萄籽油、亚麻籽油和椰子油的比例关系记作LB11,LB11=4:1:2:2。
取1kg的2'-岩藻糖基乳糖、0.22kg乳糖-N-新四糖、0.45kg乳糖-N-四糖、0.11kg的3'-唾液酸乳糖和0.22kg的6'-唾液酸乳糖,作为复合母乳低聚糖。其中,2'-岩藻糖基乳糖、乳糖-N-新四糖、乳糖-N-四糖、3'-唾液酸乳糖和6'-唾液酸乳糖的比例关系记作LB21,LB21=9:2:4:1:2。
取78.61g碳酸钙、131.00g柠檬酸钾、78.61g氯化钠、10.48g硫酸镁、0.26g硫酸亚铁、0.26g氯化钾、0.26g硫酸锌、0.26g亚硒酸钠和0.26g硫酸铜,作为复合矿物质;
取0.5g维生素A、1g维生素D、5g维生素E、0.5g维生素K、5g维生素B1、5g维生素B2、0.5g维生素B6、0.5g维生素B12、50g维生素C、1.5g泛酸、10g烟酸、220g胆碱、0.5g生物素,作为复合维生素;
巴氏奶中加入30kg脱盐乳清粉、5kg浓缩乳清蛋白粉、6kg乳糖、2kg无水奶油、5kg复合植物油、4kg的1,3-二油酸-2-棕榈酸甘油三酯粉、2kg复合母乳低聚糖、0.5kg磷脂、0.5kg的DHA藻油粉、0.2kg花生四烯酸粉剂、0.5kg碳酸钙、0.05kg核苷酸、0.3kg复合维生素、0.3kg复合矿物质,搅拌混合均匀并充分溶解,得料液M1。
4)取0.2kg樱桃粉、0.1kg树莓粉和0.1kg猕猴桃粉,作为复合果粉。其中樱桃粉、树莓粉和猕猴桃粉的比例关系记作LB31,LB31=2:1:1。
料液M1预热至60℃,于200bar的压力下进行均质,均质完成后,加热至95℃杀菌5s,冷却至室温,加入0.4kg复合果粉、1.8kg后生元,搅拌充分溶解至完全混合均匀,即得母乳化的低致敏型鲜活婴幼儿配方奶,标记为N1。
本实施例制备的母乳化的低致敏型鲜活婴幼儿配方奶适用于婴幼儿食用。
实施例2~6母乳化的低致敏型鲜活婴幼儿配方奶的制备方法
实施例2~6分别为一种母乳化的低致敏型鲜活婴幼儿配方奶的制备方法,它们的步骤与实施例1基本相同,不同之处仅在于原料用量的不同,具体详见表1~3:
表1母乳化的低致敏型鲜活婴幼儿配方奶中的原料用量及参数一览表
其中复合维生素和复合矿物质的具体成分见表2~3。
表2复合维生素的原料用量一览表
表3复合矿物质的原料用量一览表
实施例2~6其它部分的内容,与实施例1相同。
实施例7母乳化的低致敏型鲜活婴幼儿配方奶的脂肪酸含量测定
分别取实施例1~6制备的母乳化的低致敏型鲜活婴幼儿配方奶N1~N6、母乳(补充来源)、传统1段配方牛奶粉(按说明书冲调)、传统1段配方羊奶粉(按说明书冲调),按《食品中脂肪酸的测定》(GB5009.168-2016)中的方法,检测棕榈酸(C16:0)、油酸(C18:0)、亚油酸(C18:2)、α-亚麻酸(C18:3)、花生四烯酸(C20:4)和DHA(C22:6)的含量,具体结果如下:
表4脂肪酸含量测定结果一览表
母乳中的脂质具有多种重要功能,其中的脂肪酸不仅能够通过氧化分解产生能量,促进骨骼生长发育,维持机体正常的生命活动功能,还是婴幼儿脑部及神经组织的组成成分,在视力与智力发育中不可或缺。由表4可以看出,本发明提供的母乳化的低致敏型鲜活婴幼儿配方奶中含有的脂肪酸比例更接近母乳,更适合婴幼儿食用,优于传统1段配方牛奶粉和传统1段配方羊奶粉。其中,实施例1制备的母乳化的低致敏型鲜活婴幼儿配方奶N1最接近母乳。
实施例8母乳化的低致敏型鲜活婴幼儿配方奶的促进肠道双歧杆菌增殖实验
选取28只新出生C57BL/6小鼠,随机分为4组,每组7只,分别为对照组和干预组GY11~GY13,其中对照组每天早上灌胃0.2mL传统配方奶粉(按说明书冲调后0.2mL),干预组GY11~GY13一一对应灌胃0.2mL实施例1~3制备的母乳化的低致敏型鲜活婴幼儿配方奶N1~N3,持续3周,并跟踪检测1周,于第0、3、5、7、9、11、13、15、21、28天检测小鼠粪便中双歧杆菌的量。
参见图1可知,与对照组相比,母乳化的低致敏型鲜活婴幼儿配方奶能够很好的促进乳鼠肠道双歧杆菌的增殖。而双歧杆菌的增殖有助于婴幼儿肠道菌群的建立,降低过敏风险的发生,因此,母乳化的低致敏型鲜活婴幼儿配方奶更适合婴幼儿食用。其中,实施例1制备的母乳化的低致敏型鲜活婴幼儿配方奶N1最佳。
实施例9母乳化的低致敏型鲜活婴幼儿配方奶的肠道健康和免疫力影响实验
一)对照配方奶的制备
按实施例1的方法和用量制备对照配方奶,区别仅在于对照配方奶D1中不添加复合果粉和后生元,对照配方奶D2不添加复合母乳低聚糖和后生元,对照配方奶D3不添加复合母乳低聚糖和复合果粉。
二)肠道健康和免疫力影响实验
选取40只新出生C57BL/6小鼠,雌雄各半,随机分为5组,分别为对照组、干预组GY21~GY24。其中,对照组饲喂传统配方奶粉(按说明书冲调后),干预组GY21饲喂实施例1制备的母乳化的低致敏型鲜活婴幼儿配方奶N1,干预组GY22~GY24一一对应饲喂对照配方奶D1~D3。连续喂养3周,每2天记录一次体质量,每7天采集一次小鼠粪便和尾静脉血,21天时取各组小鼠的肠道组织,进行检测,检测结果见下表。
表5回肠组织中T-AOC、MDA和CAT的检测结果一览表
回肠组织中的T-AOC、CAT和MAD指标都是反映抗氧化相关的重要指标,T-AOC是全面反映抗氧化能力的指标,越高表明能力越强,越健康;同样,CAT是与过氧化物分解相关的酶,促进体内过氧化物代谢,越高表明酶活性越强。MDA是脂质发生过氧化的产物,体内的自由基可使脂质发生过氧化反应产生MDA,越高表明体内的自由基越高,过氧化反应越强,与T-AOC和CAT是指示相反的指标,越高越不健康。
由表5可以看出,干预组GY21~GY24的小鼠回肠组织中的T-AOC和CAT明显高于对照组,其中干预组G21最优。干预组GY21~GY24的小鼠回肠组织中的MAD明显低于对照组,其中干预组GY21最优。复合果粉中含有丰富的花青素和维生素C等具有抗氧化能力的物质,与复合母乳低聚糖及后生元协同增益,具有改善肠道氧化应激反应、促进乳鼠肠道健康的作用。上述实验结果证明,本发明的母乳化的低致敏型鲜活婴幼儿配方奶具有改善肠道氧化应激反应、促进乳鼠肠道健康的作用。
由图2可以看出,虽然所有的小鼠体重都有增加,但干预组GY21的增长速度明显高于其它组,说明本发明的母乳化的低致敏型鲜活婴幼儿配方奶能够加快生长速率。
分别对各组小鼠粪便和血清中IgA的含量进行测试,其中IgA越高免疫力越好。由图3可以看出,干预组GY21~GY24小鼠的粪便中IgA均高于对照组,其中GY21组最优,说明饲喂本发明的母乳化的低致敏型鲜活婴幼儿配方奶的小鼠粪便中IgA含量最高。
由图4可以看出,干预组GY21~GY24小鼠的血清中IgA均高于对照组,其中GY21组最优,说明饲喂本发明的母乳化的低致敏型鲜活婴幼儿配方奶的小鼠血清中IgA含量最高。
综上所述,本发明的母乳化的低致敏型鲜活婴幼儿配方奶中的复合母乳低聚糖、复合果粉和后生元具有协同增益的功效,能够有效增强小鼠免疫力。
进一步对各组小鼠的血清中IgE和组胺含量(IgE和组胺为过敏反应的标志物)进行测定,IgE和组胺含量越高说明小鼠越容易过敏。
由图5、图6可以看出,干预组GY21~GY24小鼠的血清中IgE和组胺均低于对照组,其中GY21组最优,说明饲喂本发明的母乳化的低致敏型鲜活婴幼儿配方奶的小鼠血清中IgE和组胺含量最低。因此,本发明的母乳化的低致敏型鲜活婴幼儿配方奶能够降低因乳源差异引起的过敏反应,降低过敏风险。
Claims (10)
1.一种母乳化的低致敏型鲜活婴幼儿配方奶,其特征在于,以重量份数计,制成它的有效成分的原料包括:
①牛乳/羊乳40~55份;
②营养剂:脱盐乳清粉20~35份、浓缩乳清蛋白粉0.5~10份、乳糖5~8份、无水奶油2~5份、复合植物油2~5份、1,3-二油酸-2-棕榈酸甘油三酯粉3~5份、复合母乳低聚糖0.5~3份、磷脂0.1~1份、DHA藻油粉0.1~0.5份、花生四烯酸粉剂0.1~0.3份、碳酸钙0.2~0.6份、核苷酸0.01~0.06份、复合维生素0.1~0.5份和复合矿物质0.1~0.3份;
③辅料:复合果粉0.1~1份和后生元0.1~2份。
2.根据权利要求1所述的母乳化的低致敏型鲜活婴幼儿配方奶,其特征在于,所述后生元是动物双歧杆菌乳亚种i797、鼠李糖乳杆菌x253、副干酪乳杆菌N1115及植物乳杆菌N3117的热灭活菌体和/或动物双歧杆菌乳亚种i797培养上清液浓缩物、鼠李糖乳杆菌x253培养上清液浓缩物、副干酪乳杆菌N1115培养上清液浓缩物及植物乳杆菌N3117培养上清液浓缩物的混合物。
3.根据权利要求1或2所述的母乳化的低致敏型鲜活婴幼儿配方奶,其特征在于,所述复合植物油是由玉米油、葡萄籽油、亚麻籽油和椰子油混合而成。
4.根据权利要求1或2所述的母乳化的低致敏型鲜活婴幼儿配方奶,其特征在于,所述复合母乳低聚糖是由2'-岩藻糖基乳糖、乳糖-N-新四糖、乳糖-N-四糖、3'-唾液酸乳糖和6'-唾液酸乳糖混合而成。
5.根据权利要求1或2所述的母乳化的低致敏型鲜活婴幼儿配方奶,其特征在于,所述复合果粉是由樱桃粉、树莓粉和猕猴桃粉混合而成。
6.根据权利要求1或2所述的母乳化的低致敏型鲜活婴幼儿配方奶,其特征在于,所述牛乳/羊乳是生牛乳/生羊乳经标准化、杂质分离制得。
7.权利要求1-6中任一项所述的母乳化的低致敏型鲜活婴幼儿配方奶的一种制备方法,其特征在于,它是取牛乳/羊乳经巴氏杀菌后,加入营养剂混匀,再经均质、杀菌、冷却,然后加入辅料混匀,即得所述母乳化的低致敏型鲜活婴幼儿配方奶。
8.根据权利要求7所述的母乳化的低致敏型鲜活婴幼儿配方奶的制备方法,其特征在于,所述加入营养剂混匀后且所述均质前,还需预热至60~65℃。
9.根据权利要求7或8所述的母乳化的低致敏型鲜活婴幼儿配方奶的制备方法,其特征在于,所述均质的压力为190~210bar。
10.根据权利要求7或8所述的母乳化的低致敏型鲜活婴幼儿配方奶的制备方法,其特征在于,所述巴氏杀菌的温度为52~58℃、时间为5~10s;
所述杀菌的温度为90~100℃、时间为5~10s。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011441206.XA CN112535217A (zh) | 2020-12-08 | 2020-12-08 | 母乳化的低致敏型鲜活婴幼儿配方奶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011441206.XA CN112535217A (zh) | 2020-12-08 | 2020-12-08 | 母乳化的低致敏型鲜活婴幼儿配方奶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112535217A true CN112535217A (zh) | 2021-03-23 |
Family
ID=75019991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011441206.XA Withdrawn CN112535217A (zh) | 2020-12-08 | 2020-12-08 | 母乳化的低致敏型鲜活婴幼儿配方奶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112535217A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114886119A (zh) * | 2022-06-10 | 2022-08-12 | 江南大学 | 3’-唾液酸乳糖在制备缓解食物过敏的功能性食品中的应用 |
WO2023241110A1 (zh) * | 2022-06-15 | 2023-12-21 | 黑龙江飞鹤乳业有限公司 | 营养组合物、包含其的食品以及该营养组合物的用途 |
-
2020
- 2020-12-08 CN CN202011441206.XA patent/CN112535217A/zh not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114886119A (zh) * | 2022-06-10 | 2022-08-12 | 江南大学 | 3’-唾液酸乳糖在制备缓解食物过敏的功能性食品中的应用 |
CN114886119B (zh) * | 2022-06-10 | 2023-11-28 | 江南大学 | 3’-唾液酸乳糖在制备缓解食物过敏的功能性食品中的应用 |
WO2023241110A1 (zh) * | 2022-06-15 | 2023-12-21 | 黑龙江飞鹤乳业有限公司 | 营养组合物、包含其的食品以及该营养组合物的用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101411679B1 (ko) | 장내 세균총 생육 촉진 방법 및 지질 조성물 | |
Beheshtipour et al. | Supplementation of Spirulina platensis and Chlorella vulgaris algae into probiotic fermented milks | |
CN1838888B (zh) | 婴儿或第二阶段配方奶 | |
CN111227045B (zh) | 乳制品在促进哺乳动物身长增长中的应用 | |
EP2295535A1 (en) | Probiotic material | |
CN112535218A (zh) | 促进智力发育和肠道健康的母乳化婴幼儿配方奶粉及其制备方法和应用 | |
JP7088829B2 (ja) | 新生児向けの脳機能改善用組成物 | |
CN108244252A (zh) | 益生菌多元蛋白粉及其制备方法 | |
CN109430407A (zh) | 益生菌组合制剂 | |
AU2020294253B2 (en) | Nutritional Composition For Promoting Intestinal Health | |
CN112790250A (zh) | 促进肠道健康的婴儿配方奶粉及其制备方法 | |
TW201306759A (zh) | 包括乳鐵蛋白之營養組成物於刺激免疫細胞上之用途 | |
RU2687038C1 (ru) | Соответствующие возрастным потребностям питательные композиции с различным содержанием белка | |
US20190201459A1 (en) | Anti-allergic agent for infants | |
CN112955163A (zh) | 用于治疗炎性相关胃肠障碍的益生菌组合 | |
CN112535217A (zh) | 母乳化的低致敏型鲜活婴幼儿配方奶及其制备方法 | |
US20200315235A1 (en) | Normalization of the Intestinal Microbiota Composition in Infants or Toddlers Fed with an Amino Acid-Based Nutritional Composition | |
CN111919890A (zh) | 提高免疫力降低血糖血脂的中老年配方奶粉及其制备方法 | |
CN107668721A (zh) | 包含乳铁蛋白的营养组合物在支持抵抗疾病和状况中的用途 | |
RU2426438C2 (ru) | Синбиотическая композиция для коррекции нарушений микробиоценоза кишечника и повышения общей резистентности организма и способ ее получения (варианты) | |
CN112075504A (zh) | 增强免疫力的婴儿配方牛奶粉 | |
EP2746398A1 (en) | Process for producing conjugated linolenic acid from linolenic acid employing Bifidobacterium breve, Bifidobacterium bifidum, or Lactobacillus oris strains. | |
CN111227046B (zh) | 乳制品在改善婴幼儿肠道SIgA水平中的应用 | |
Singh et al. | Development of probiotics and prebiotics product as weaning food for infants | |
CN112655774A (zh) | 促进大脑发育的婴儿配方奶粉及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210323 |
|
WW01 | Invention patent application withdrawn after publication |